Posting of Basic Results of Clinical Trials (REGIST)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01658254
First received: June 20, 2012
Last updated: September 29, 2014
Last verified: June 2012
  Purpose

The gap between the high number of registered trials and the few ones where results were available (in registries or in journals) has been identified as a major problem distorting the scientific evidence available. As a consequence, the FDAAA (Food and Drug Administration Amendments Act) added on September 27, 2007 a requirements policy regarding publication of summary results on the publicly accessible registry ClinicalTrials.gov. Reporting of summary results is required for "applicable clinical trials" no later than one year after the "primary completion date", i.e. the date of collection of primary outcome data on the last patient to be enrolled. 'Applicable clinical trials', is the term used in the FDAAA to designate trials that may be subject to the registration and reporting requirements.

Not complying with the reporting requirements can result in penalties, such as withholding of National Institute of Health grant or funding and civil monetary penalties of up to $10,000 a day. Despite the possibility of incurring penalties for not complying with the posting requirement, compliance remains globally poor.

In this current study, the primary objective will be to test the hypothesis that sending an email looking as a survey, reminding the necessity of posting results to the trials' responsible parties registered in ClinicalTrials.gov and subject to mandatory reporting but not complying with it, will increase the results posting rate.


Condition Intervention
The Study Will Focus on no Specific Conditions
Other: survey by email

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Health Services Research
Official Title: A Cohort Randomized Controlled Trial Evaluating the Effect of Sending a Reminder to Responsible Parties of Clinical Trials in the Posting of Basic Results Onto ClinicalTrials.Gov

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • The proportions of trials with posted results at 90 days will be compared using a chi-square test to the control group. [ Time Frame: 90 days ] [ Designated as safety issue: No ]
    Primary endpoint: the proportions of trials with posted results on the registry at 90 days will be compared to the control group using a chi-square test.


Secondary Outcome Measures:
  • The proportions of trials with posted results on the registry at 180 days will be compared to the control group using a chi-square test. [ Time Frame: 180 days ] [ Designated as safety issue: No ]

Enrollment: 379
Study Start Date: September 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Survey by email
One arm of investigators will receive the survey to answer by email, reminding the necessity of posting basic results
Other: survey by email
The intervention consists in an email to be sent to the sponsor and/or principal investigator of randomly assigned trials. This email will notify them that their trial's primary completion date is over a year old and will ask the reasons why they have not posted results on the registry. Several reasons will be proposed, and investigators or sponsors will be asked to reply by sending back an email or through a website where the same questions will appear. A follow-up email will systematically be sent 7 days after, with similar content (appendix2). The emails will be sent as direct emails, without attached files, with the edit subject "Posting basic results". The controlled group will receive no intervention.
No Intervention: Non interventional arm
This arm will receive no intervention (no email with the survey)

Detailed Description:

According to the recommendation of 2005 by International Committee of Medical Journal Editors (ICMJE), clinical trials must be registered before enrolment of the first patient in a free registry recognized by the World Health Organization (WHO). The goal is to improve transparency of clinical research. The ClinicalTrials.gov trial registry, initiated subsequently to the US Food and Drug Administration Modernization Act (FDAMA) in 1997, is the widest used registry, and contains more than 121 000 studies located in 179 countries (data of March 1, 2012).

The gap between the high number of registered trials and the few ones where results were available (in registries or in journals) has been identified as a major problem distorting the scientific evidence available, and inducing publication bias. As a consequence, the FDAAA (Food and Drug Administration Amendments Act) added on September 27, 2007 a requirements policy regarding publication of summary results on the publicly accessible registry ClinicalTrials.gov. Reporting of summary results is required for "applicable clinical trials" no later than one year after the "primary completion date", i.e. the date of collection of primary outcome data on the last patient to be enrolled. 'Applicable clinical trials', is the term used in the FDAAA to designate trials that may be subject to the registration and reporting requirements. They include interventional controlled studies registered after the enactment of the FDAAA (or ongoing at this date), involving drugs, biologics, or devices (only after FDA-approved for any use), regardless of sponsorship; phases II through IV; located at least in one U.S. site.

The entity or individual responsible for registering and posting basic results is called the 'responsible party'. This term refers to the sponsor of the study or the principal investigator of the study, if so designated by a sponsor, grantee, contractor, or awardee.

In certain circumstances, delayed submission of results information with certification can be allowed. Not complying with the reporting requirements can result in penalties, such as withholding of National Institute of Health grant or funding and civil monetary penalties of up to $10,000 a day. Despite the possibility of incurring penalties for not complying with the posting requirement, compliance remains globally poor.

In this current study, the primary objective will be to test the hypothesis that sending an email asking to answer a survey, reminding the necessity of posting results to the trials' responsible parties registered in ClinicalTrials.gov and subject to mandatory reporting but not complying with it, will increase the results posting rate.

The secondary objective will be to investigate the reasons given by the trials' responsible parties for not posting summary results onto the registry.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Interventional studies of drugs, biological or devices
  • Studies which are closed and either completed or active but not recruiting anymore
  • Studies with at least one site in the USA
  • Studies registered as phase IV
  • Studies with a primary completion date or, if missing, a completion date ranging from October 2008 to January 2011
  • Studies without posted results on the registry

Exclusion Criteria:

  • Studies which are still recruiting
  • Studies which are either withdrawn or suspended
  • Studies which primary completion date is less than one year
  • Studies without a given primary completion date or completion date
  • Studies involving interventions which are neither drugs or biologics nor devices will be excluded
  • Studies whose summary results are posted
  • Studies without indication on the sponsor or the principal investigator
  • Studies whom email address of the sponsor or the principal investigator could not be found in a publicly accessible site
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01658254

Locations
France
Clinical Epidemiology Center, Hotel-Dieu
Paris, France, 75004
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Philippe Ravaud, MD, PhD Hotel-Dieu, Clinical Epidemiology Center
  More Information

No publications provided

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT01658254     History of Changes
Other Study ID Numbers: PR 738
Study First Received: June 20, 2012
Last Updated: September 29, 2014
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Clinical trials
Basic results
Registry

ClinicalTrials.gov processed this record on October 23, 2014